Use of Sacubitril/valsartan in patients with cardio toxicity and heart failure due to chemotherapy.

Autor: Gregorietti V; Cardio-Oncology Department, Roffo Institute, 5481 Av San Martin. CABA,, Buenos Aires, Argentina., Fernandez TL; Cardiology Department, La Paz University Hospital, Madrid, Spain., Costa D; Cardio-Oncology Department, Roffo Institute, 5481 Av San Martin. CABA,, Buenos Aires, Argentina., Chahla EO; Cardio-Oncology Department, Roffo Institute, 5481 Av San Martin. CABA,, Buenos Aires, Argentina., Daniele AJ; Cardio-Oncology Department, Roffo Institute, 5481 Av San Martin. CABA,, Buenos Aires, Argentina. ajdaniele@gmail.com.
Jazyk: angličtina
Zdroj: Cardio-oncology (London, England) [Cardiooncology] 2020 Nov 05; Vol. 6 (1), pp. 24. Date of Electronic Publication: 2020 Nov 05.
DOI: 10.1186/s40959-020-00078-4
Abstrakt: Background: Cancer therapy-related cardiac dysfunction (CTRCD) is a critical problem with an impact on both oncological and cardiovascular prognosis, especially when it prevents patients from receiving cancer treatment. Standard therapy for heart failure (HF) is recommended for CTRCD, but there is no well-established evidence on how sacubitril/valsartan may help cancer patients with cardiotoxicity.
Objectives: The aim of this trial was to study the effectiveness of sacubitril-valsartan in patients with CTRCD treated in cardio-oncology units.
Methods: We enrolled 635 patients with breast cancer and followed them with echocardiography and NT- proBNP. Patients who developed left ventricular dysfunction and heart failure were treated with angiotensin-converting enzyme inhibitors (ACEI) (enalapril) or angiotensin receptor blockers (ARB) (valsartan), aldosterone antagonists (eplerenone), digitalis and diuretics (furosemide), as needed. When patients remained symptomatic and met the PARADIGM-HF inclusion criteria, sacubitril/valsartan was started instead of enalapril or valsartan. We analyzed clinical, laboratory and echocardiographic variables to determine the beneficial effects of sacubitril/valsartan on left ventricular remodeling (improvement of left ventricular ejection fraction (LVEF), left ventricle internal diameter in diastole), diastolic dysfunction (E/e' ratio), reduction in NT-proBNP levels, New York Heart Association (NHYA) class and improvement in the 6-min walk test. Also, we analyzed serum creatinine and potassium levels to determine treatmentsafety in this population. Median follow-up was 20 months.
Results: Twenty-eight patients developed cardiotoxicity and were treated with sacubitril/valsartan. The sacubitril/valsartan dose was 100 mg (sacubitril 49 mg/valsartan 51 mg) in 12 patients (42.85%) and 200 mg (sacubitril 97 mg/valsartan 103 mg) in 16 patients (57.15%). No deaths were reported, and one patient underwent heart transplantation. Baseline median NT-proBNP was 997.5 pg/ml (IQR 663.8 - 2380.8), which decreased to a median of 416.5 pg/ml (IQR 192.0-798.2) on follow-up with p < 0.001. Baseline NYHA functional class was III (78.6%) or IV (21.4%), and it improved to I (57.1%) or II (42.9%) on follow-up. LVEF increased with treatment from 26.7 ± 5.4% to 32.3 ± 5.5% (p < 0.001). There were also significant improvements in left ventricle internal diameter in diastole (LVIDD), diastolic function, 6-min walk test, and mitral valve regurgitation. There were no differences between basal and follow-up levels of serum creatinine or potassium.
Conclusion: Sacubitril/valsartan might be a promising treatment option in patients with refractory CTRCD.
Databáze: MEDLINE
Externí odkaz: